Coherus: Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes
(RTTNews) - Coherus BioSciences, Inc. (CHRS) Tuesday said it has agreed to buy back about $170 million of its 1.500% convertible senior subordinated notes due 2026 at its principal plus interest amount.
Read full article »
Chairman & CEO
Dennis M. Lanfear
Coherus is a California-based biopharmaceutical company that develops and commercializes biosimilar therapeutics for the treatment of cancer.
Read more